Published in J Neurovirol on July 19, 2012
Neuroprotective function of 14-3-3 proteins in neurodegeneration. Biomed Res Int (2013) 0.87
Leucine-rich repeat kinase 2 modulates neuroinflammation and neurotoxicity in models of human immunodeficiency virus 1-associated neurocognitive disorders. J Neurosci (2015) 0.80
YWHAE/14-3-3ε: a potential novel genetic risk factor and CSF biomarker for HIV neurocognitive impairment. J Neurovirol (2013) 0.78
Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell (1991) 13.69
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol (1995) 7.57
14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol (2000) 6.94
HIV-1 accessory proteins--ensuring viral survival in a hostile environment. Cell Host Microbe (2008) 5.90
Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis (2001) 5.27
The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med (1996) 5.06
Identification of HIV-1 vpr product and function. J Acquir Immune Defic Syndr (1990) 4.35
Human immunodeficiency virus vpr product is a virion-associated regulatory protein. J Virol (1990) 4.35
How do 14-3-3 proteins work?-- Gatekeeper phosphorylation and the molecular anvil hypothesis. FEBS Lett (2002) 4.08
14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation. Mol Cell (2000) 4.05
Identification of a protein encoded by the vpu gene of HIV-1. Nature (1988) 4.05
Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding. Mol Cell (1999) 4.02
14-3-3 proteins: a historic overview. Semin Cancer Biol (2006) 3.91
Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature (1994) 3.87
HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci (2007) 3.73
HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat Med (1998) 3.61
The HIV Env-mediated fusion reaction. Biochim Biophys Acta (2003) 3.37
14-3-3 proteins: regulation of subcellular localization by molecular interference. Cell Signal (2000) 3.06
Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology (2000) 3.03
Human immunodeficiency virus-associated dementia: an evolving disease. J Neurovirol (2003) 2.93
HIV-1 Vpr interacts with the nuclear transport pathway to promote macrophage infection. Genes Dev (1998) 2.82
Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol (1997) 2.82
Host factors exploited by retroviruses. Nat Rev Microbiol (2007) 2.79
Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection. J Exp Med (1997) 2.75
Structure of a 14-3-3 protein and implications for coordination of multiple signalling pathways. Nature (1995) 2.68
Increased LIS1 expression affects human and mouse brain development. Nat Genet (2009) 2.45
The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: a 10-year review. J Neurol Neurosurg Psychiatry (2010) 2.29
14-3-3epsilon is important for neuronal migration by binding to NUDEL: a molecular explanation for Miller-Dieker syndrome. Nat Genet (2003) 2.27
The dynamics of cell cycle regulation. Bioessays (2002) 2.21
HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLoS Pathog (2007) 2.13
Mutual functional destruction of HIV-1 Vpu and host TASK-1 channel. Mol Cell (2004) 2.05
14-3-3 proteins in the nervous system. Nat Rev Neurosci (2003) 2.02
Pharmacological chaperones: potential treatment for conformational diseases. Trends Endocrinol Metab (2004) 1.96
14-3-3 proteins: a highly conserved, widespread family of eukaryotic proteins. Trends Biochem Sci (1992) 1.89
Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Ann Neurol (2011) 1.86
Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology (2002) 1.84
Biochemical mechanism of HIV-I Vpr function. Specific interaction with a cellular protein. J Biol Chem (1994) 1.79
Models of neuronal injury in AIDS: another role for the NMDA receptor? Trends Neurosci (1992) 1.78
How to improve the clinical diagnosis of Creutzfeldt-Jakob disease. Brain (1999) 1.71
HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci (2007) 1.64
Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis (2007) 1.63
Refinement of a 400-kb critical region allows genotypic differentiation between isolated lissencephaly, Miller-Dieker syndrome, and other phenotypes secondary to deletions of 17p13.3. Am J Hum Genet (2003) 1.61
Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol (2000) 1.61
Structural basis of 14-3-3 protein functions. Semin Cell Dev Biol (2011) 1.60
Evolution of HIV dementia with HIV infection. Int Rev Psychiatry (2008) 1.58
Further molecular and clinical delineation of co-locating 17p13.3 microdeletions and microduplications that show distinctive phenotypes. J Med Genet (2010) 1.50
Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt-Jakob disease. Neurology (2004) 1.49
Current clinical diagnosis in Creutzfeldt-Jakob disease: identification of uncommon variants. Ann Neurol (2000) 1.49
Specificity of 14-3-3 isoform dimer interactions and phosphorylation. Biochem Soc Trans (2002) 1.40
Apoptosis induced by HIV-1 infection of the central nervous system. J Clin Invest (1996) 1.40
Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (2001) 1.39
Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates. Neurology (2000) 1.36
Patterns of CCR5, CXCR4, and CCR3 usage by envelope glycoproteins from human immunodeficiency virus type 1 primary isolates. J Virol (1998) 1.33
Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. J Biol Chem (1995) 1.32
Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry (2001) 1.30
Biochemical mechanism of HIV-1 Vpr function. Oligomerization mediated by the N-terminal domain. J Biol Chem (1994) 1.30
Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res (2011) 1.29
Neurocognitive impairment and HIV risk factors: a reciprocal relationship. AIDS Behav (2010) 1.29
14-3-3 proteins: regulators of numerous eukaryotic proteins. IUBMB Life (2005) 1.27
Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology (2010) 1.26
Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep (2011) 1.26
Molecular evolution of the 14-3-3 protein family. J Mol Evol (1996) 1.25
HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS (2011) 1.23
Identification of YWHAE, a gene encoding 14-3-3epsilon, as a possible susceptibility gene for schizophrenia. Hum Mol Genet (2008) 1.23
Subcellular localisation of 14-3-3 isoforms in rat brain using specific antibodies. J Neurochem (1994) 1.21
Direct interaction between protein kinase C theta (PKC theta) and 14-3-3 tau in T cells: 14-3-3 overexpression results in inhibition of PKC theta translocation and function. Mol Cell Biol (1996) 1.20
HIV-1 Vpr induces cell cycle G2 arrest in fission yeast (Schizosaccharomyces pombe) through a pathway involving regulatory and catalytic subunits of PP2A and acting on both Wee1 and Cdc25. Virology (2001) 1.17
Binding of 14-3-3beta to the carboxyl terminus of Wee1 increases Wee1 stability, kinase activity, and G2-M cell population. Cell Growth Differ (2000) 1.17
HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. Retrovirology (2011) 1.17
Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders Ann Neurol (1999) 1.16
14-3-3zeta is an effector of tau protein phosphorylation. J Biol Chem (2000) 1.15
Requirement for macrophages in neuronal injury induced by HIV envelope protein gp120. Neuroreport (1992) 1.15
Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1. J Virol (2000) 1.14
Hippocampal dysregulation of synaptic plasticity-associated proteins with age-related cognitive decline. Neurobiol Dis (2011) 1.14
14-3-3 proteins: biological function and domain structure. Biochem Soc Trans (1995) 1.14
Vpr protein of human immunodeficiency virus type 1 binds to 14-3-3 proteins and facilitates complex formation with Cdc25C: implications for cell cycle arrest. J Virol (2005) 1.13
Regulation of neural cell survival by HIV-1 infection. Neurobiol Dis (2005) 1.13
HIV-1 gp120- and gp160-induced apoptosis in cultured endothelial cells is mediated by caspases. Blood (2000) 1.12
The HIV nef protein associates with protein kinase C theta. J Biol Chem (1996) 1.12
Human 14-3-3 protein: radioimmunoassay, tissue distribution, and cerebrospinal fluid levels in patients with neurological disorders. J Neurochem (1982) 1.12
Clinical diagnosis and differential diagnosis of CJD and vCJD. With special emphasis on laboratory tests. APMIS (2002) 1.10
Neuronal number and volume alterations in the neocortex of HIV infected individuals. J Neurol Neurosurg Psychiatry (1993) 1.09
Laboratory diagnosis of central nervous system infections. Infect Dis Clin North Am (2001) 1.09
Genomic copy number variations at 17p13.3 and epileptogenesis. Epilepsy Res (2010) 1.09
14-3-3 protein in the CSF of patients with rapidly progressive dementia. Neurology (2003) 1.05
Sequencing of DISC1 pathway genes reveals increased burden of rare missense variants in schizophrenia patients from a northern Swedish population. PLoS One (2011) 1.05
Mechanisms of HIV-1 Nef function and intracellular signaling. J Neuroimmune Pharmacol (2011) 1.04
Partner molecules of accessory protein Vpr of the human immunodeficiency virus type 1. DNA Cell Biol (2004) 1.03
Specification of 14-3-3 proteins in Lewy bodies. Ann Neurol (2003) 1.02
Anti-apoptotic actions of PPAR-gamma against ischemic stroke. Mol Neurobiol (2010) 1.02
Human immunodeficiency virus type 1 gp120-mediated disruption of tight junction proteins by induction of proteasome-mediated degradation of zonula occludens-1 and -2 in human brain microvascular endothelial cells. J Neurovirol (2008) 1.01
Hepatitis C virus differentially modulates activation of forkhead transcription factors and insulin-induced metabolic gene expression. J Virol (2010) 1.00
Genetic isolation of transport signals directing cell surface expression. Nat Cell Biol (2005) 1.00
14-3-3 proteins in neurodegeneration. Semin Cell Dev Biol (2011) 0.99
Immunolocalisation of 14-3-3 isoforms in normal and scrapie-infected murine brain. Neuroscience (2002) 0.99
The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's disease. Neurobiol Aging (2008) 0.99
Deletion of YWHAE in a patient with periventricular heterotopias and pronounced corpus callosum hypoplasia. J Med Genet (2009) 0.97
G protein-coupled receptors in HIV and SIV entry: new perspectives on lentivirus-host interactions and on the utility of animal models. Semin Immunol (1998) 0.97
Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurochem (1999) 0.97
Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell (2003) 2.50
Effects of sex on object recognition and spatial navigation in humans. Behav Brain Res (2006) 1.04
The use and validation of the spatial navigation Memory Island test in primary school children. Behav Brain Res (2010) 0.91
Abnormalities in parentally rated executive function in methamphetamine/polysubstance exposed children. Pharmacol Biochem Behav (2011) 0.88
Apolipoprotein E Allelic Frequency Altered in Women with Early-onset Breast Cancer. Breast Cancer (Auckl) (2010) 0.88
Drosophila mixed lineage kinase/slipper, a missing biochemical link in Drosophila JNK signaling. Biochim Biophys Acta (2003) 0.88
Adult neuronal Arf6 controls ethanol-induced behavior with Arfaptin downstream of Rac1 and RhoGAP18B. J Neurosci (2012) 0.86
Apolipoprotein E polymorphisms and spontaneous pregnancy loss in patients with endometriosis. Mol Hum Reprod (2012) 0.84
Long-lasting, experience-dependent alcohol preference in Drosophila. Addict Biol (2013) 0.83
Age, sex, and handedness differentially contribute to neurospatial function on the Memory Island and Novel-Image Novel-Location tests. Physiol Behav (2011) 0.81
The Relationship between Visuospatial Memory and Coping Strategies in Breast Cancer Survivors. Breast Cancer (Auckl) (2011) 0.81
14-3-3ε Is required for germ cell migration in Drosophila. PLoS One (2012) 0.79
The role of the actin cytoskeleton in regulating Drosophila behavior. Rev Neurosci (2013) 0.78
Developmental methamphetamine exposure results in short- and long-term alterations in hypothalamic-pituitary-adrenal-axis-associated proteins. Dev Neurosci (2013) 0.78
YWHAE/14-3-3ε: a potential novel genetic risk factor and CSF biomarker for HIV neurocognitive impairment. J Neurovirol (2013) 0.78
Translational spatial task and its relationship to HIV-associated neurocognitive disorders and apolipoprotein E in HIV-seropositive women. J Neurovirol (2012) 0.77